J Appl Biomed 3:67-73, 2005 | DOI: 10.32725/jab.2005.008

Neuroprotective peptides as drug candidates against Alzheimer's diasease

Jiří Patočka1,2,*, Jiřina Slaninová3, Gabriela Kunešová1
1 Department of Toxicology, School of Military Health Sciences, University of Defence, Hradec Králové, Czech Republic
2 Department of Radiobiology and Toxicology, Faculty of Health and Social Studies, University of South Bohemia, České Budějovice, Czech Republic
3 Institute of Organic Chemistry and Biochemistry, Academy of Sciences, Praha, Czech Republic

First described by Alois Alzheimer in 1907, Alzheimer's disease (AD) is the most common dementia type, affecting approximately 20 million people worldwide. As the population is getting older, AD is a growing health problem. AD is characterized by the presence of neuritic plaques containing the amyloid-beta peptide (Abeta) and an intraneuronal accumulation of tubule-associated protein called tau. Currently available treatment used in AD is based on acetylcholinesterase inhibitors, since in the course of AD there is a substantial loss in cholinergic neurons. Another registered drug used in more severe AD is the NMDA antagonist-memantine. From a drug development point of view, some potential new AD therapeutics include neuroprotective peptides that may act in a variety of different ways, e.g. they help to break the amyloid plaque formation, modulate peptide processing enzymes (secretases) or are able to degrade Abeta toxic peptide. In this review, we present an overview of the new classes of compounds in use against AD.

Keywords: Alzheimer's disease; neuroprotective peptide; Abeta peptide

Received: November 5, 2004; Revised: December 6, 2004; Published: July 31, 2005  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Patočka J, Slaninová J, Kunešová G. Neuroprotective peptides as drug candidates against Alzheimer's diasease. J Appl Biomed. 2005;3(2):67-73. doi: 10.32725/jab.2005.008.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Alcalay R.N., Giladi E., Pick C.G., Gozes I.: Intranasal administration of NAP, a neuroprotective peptide, decreases anxiety-like behavior in aging mice in the elevated plus maze. Neurosci. Lett. 361:128-131, 2004. Go to original source... Go to PubMed...
    2. Bassan M., Zamostiano R., Davidson A. et al.: Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide. J. Neurochem. 72:1283-1293, 1999. Go to original source... Go to PubMed...
    3. Beni-Adani L., Gozes I., Cohen Y. et al.: A peptide derived from activity-dependent neuroprotective protein (ADNP) ameliorates injury response in closed head injured mice. J. Pharmacol. Exp. Ther. 296:57-63, 2000.
    4. Blondel O., Collin C., McCarran B. et al.: A glia-derived signal regulating neuronal differentiation. J. Neurosci. 20:8012-8020, 2000. Go to original source... Go to PubMed...
    5. Brenneman D.E., Spong C.Y., Hauser J.M. et al.: Protective peptides that are orally active and mechanistically nonchiral. J.Pharm.Exp.Ther. 309:1190-1197, 2004. Go to original source... Go to PubMed...
    6. Brenneman D.E., Gozes I.: A femtomolar-acting neuroprotective peptide. J. Clin. Incest. 97: 2299-2307, 1996. Go to original source... Go to PubMed...
    7. Brenneman D.E., Hauser J., Neale E. et al.: Activity-dependent neurotrophic factor: structure-activity relationships of femtomolar-acting peptides. J. Pharmacol. Exp. Ther. 285:619-627, 1998.
    8. Chacon M.A., Barria M.I., Soto C., Inestrosa N.C.: Beta-sheet breaker peptide prevents Abeta-induced spatial memory impairments with partial reduction of amyloid deposits. Mol. Psychiatry. 9:953-961, 2004. Go to original source... Go to PubMed...
    9. Counts S.E., Perez S.E., Ginsberg S.D., DeLacalle S., Mufson E.J.: Galanin in Alzheimer disease. Mol. Interv. 3:137-156, 2004. Go to original source...
    10. Counts S.E., Perez S.E., Kahl U.: Galanin: neurobiologic mechanisms and therapeutic potential for Alzheimer's disease. CNS Drug Rev. 7:445-470, 2001. Go to original source... Go to PubMed...
    11. Craft S., Asthana S., Newcomer J.W. et al.: Enhancement of memory in Alzheimer disease with insulin and somatostatin, but not glucose. Arch. Gen. Psychiatry 56:1135-1140, 1999. Go to original source... Go to PubMed...
    12. Croom J., Taylor I.L.: Neuropeptide Y, peptide YY and aluminum in Alzheimer's disease: is there an etiological relationship? J. Inorg. Biochem. 87:51-56, 2001. Go to original source... Go to PubMed...
    13. Dejda A., Matczak I., Nosák J.Z.: Postepy. Hig. Med. Dosw. 58:18-26, 2004.
    14. Eldar-Finkelman H.: Glycogen synthase kinase 3: an emerging therapeutic target. Trends Mol. Med. 8:126-132, 2002. Go to original source... Go to PubMed...
    15. Fisher A., Hanin I.: Potential animal models for senile dementia of Alzheimer's type, with emphasis on AF64A-induced cholinotoxicity. Annu. Rev. Pharmacol. Toxicol. 26:161-81, 1986. Go to original source... Go to PubMed...
    16. Glazner G.W., Camandola S., Mattson M.P.: Nuclear factor kappa B mediates the cell survival-promoting action of activity dependent neurotrophic factor peptide-9. J. Neurochem. 75:101-108, 2000. Go to original source... Go to PubMed...
    17. Gotz J., Chen F., van Dorpe J., Nitsch R.M.: Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science 293:1491-1495, 2001. Go to original source... Go to PubMed...
    18. Gozes I., Spier A.S.: Peptides as drug targets to Alzheimer's disease. Drug Develop. Res. 56:47581, 2002. Go to original source...
    19. Gozes I.: Neuroprotective peptide drug delivery and development: potential new therapeutics. Trends Neurosci. 24:700-705, 2001. Go to original source... Go to PubMed...
    20. Gozes I., Brenneman D.E. : VIP molecular biology and neurobiological function. Mol. Neurobiol. 3:201-236, 1989. Go to original source... Go to PubMed...
    21. Gozes I., Giladi E., Pinhasov A., Bardea A., Brenneman D.E.: Activity-dependent neurotrophic factor: intranasal administration of femtomolar-acting peptides improve performance in a watermaze. J. Pharmacol. Exp. Ther. 93:1091-1098, 2000.
    22. Gozes I., Divinsky I., Pilzer I. et al.: From vasoactive intestinal peptide (VIP) through activity-dependent neuroprotective protein (ADNP) to NAP: a view of neuroprotection and cell division. J. Mol. Neurosci 20:315-322, 2004. Go to original source...
    23. Gozes I., Fridkin M., Hill J.M, Brenneman D.E.: Pharmaceutical VIP: prospects and problems. Curr. Med. Chem. 6:1019-1034, 1999. Go to original source...
    24. Gozes I., Alcalay R., Giladi E. et al.: NAP: a neuroprotective peptide. J. Mol. Neurosci. 19:175-178, 2002. Go to original source...
    25. Gozes I., Steingart R.A., Spier A.D.: NAP mechanisms of neuroprotection. J. Mol. Neurosci. 24:67-72, 2004. Go to original source... Go to PubMed...
    26. Gressens P., Marret S., Bodenant C., Schwendimann L., Evrard P.: Activity-dependent neurotrophic factor-14 requires protein kinase C and mitogen-associated protein kinase kinase activation to protect the developing mouse brain against excitotoxicity. J. Mol. Neurosci. 13: 199-210, 1999. Go to original source... Go to PubMed...
    27. Guo Q., Sebastian L., Sopher B.L. et al.: Neurotrophic factors [activity-dependent neurotrophic factor (ADNF) and basic fibroblast growth factor (bFGF)] interrupt excitotoxic neurodegenerative cascades promoted by a PS1 mutation. Proc. Natl. Acad. Sci. USA 96:4125-4130, 1999. Go to original source... Go to PubMed...
    28. Guo Z.H., Mattson M.P.: Neurotrophic factors protect cortical synaptic terminals against amyloid and oxidative stress-induced impairment of glucose transport, glutamate transport and mitochondrial function. Cereb. Cortex 10:50-57, 2000. Go to original source... Go to PubMed...
    29. Hashimoto Y., Ito Y., Niikura T. et al.: Mechanisms of neuroprotection by a novel rescue factor humanin from Swedish mutant amyloid precursor protein. Biochem. Biophys. Res. Commun. 283:460-468, 2001. Go to original source... Go to PubMed...
    30. Hirouchi M.: Current status and perspectives on the development of therapeutic agents for Alzheimer's disease. (Article in Japanese) Nippon Yakurigaku Zasshi. 123:421-427, 2004. Go to original source... Go to PubMed...
    31. Ioudina M., Uemura E.: A three amino acid peptide, Gly-Pro-Arg, protects and rescues cell death induced by amyloid beta-peptide. Exp. Neurol. 184:923-929, 2004. Go to original source...
    32. Jaarsma D., Veenma-van der Duin L., Korf J.: N-acetylaspartate and N-acetylaspartylglutamate levels in Alzheimer's disease post-mortem brain tissue. J.Neurol. Sci. 127:230-233, 1994. Go to original source... Go to PubMed...
    33. Jhamandas J.H., Harris K.H., MacTavish D., Jassar B.S.: Novel excitatory actions of galanin on rat cholinergic basal forebrain neurons: implications for its role in Alzheimer's disease. J. Neurophysiol. 87:696-704, 2002. Go to original source... Go to PubMed...
    34. Krejčová G., Patočka J., Slaninová J.: Effect of humanin analogues on experimentally induced impairment of spatial memory in rats. J. Pept. Sci. 10:636-639, 2004. Go to original source... Go to PubMed...
    35. Lin K.F., Chang R.C., Suen K.C., So K.F., Hugon J.: Modulation of calcium/calmodulin kinase-II provides partial neuroprotection against beta-amyloid peptide toxicity. Eur. J. Neurosci 19:2047-2055, 2004. Go to original source... Go to PubMed...
    36. Mamiya T., Ukai M.: [Gly(14)]-Humanin improved the learning and memory impairment induced by scopolamine in vivo. Br. J. Pharmacol. 134:1597-1599, 2001. Go to original source... Go to PubMed...
    37. Mileusnic R., Lancashire C.L., Rose S.P.: The peptide sequence Arg-Glu-Arg, present in the amyloid precursor protein, protects against memory loss caused by A beta and acts as a cognitive enhancer. Eur. J. Neurosci. 19:1933-1938, 2004. Go to original source...
    38. Nieoullon A.: Alzheimer's disease: neurobiological advances supporting proposals for new therapeutical approaches. J. Appl. Biomed. 2:123-130, 2004. Go to original source...
    39. Niikura T., Yamada M., Chiba T. S. et al.: Characterization of V642I-AbetaPP-induced cytotoxicity in primary neurons. J. Neurosci. Res. 77:54-62, 2004. Go to original source... Go to PubMed...
    40. Orlando L.R., Luthi-Carter R., Standaert D.G. et al.: N-acetylaspartylglutamate (NAAG) protects against rat striatal quinolinic acid lesions in vivo. Neurosci. Lett. 236:91-94, 1997. Go to original source... Go to PubMed...
    41. Passani L.A., Vonsattel J.P., Carter R.E., Coyle J.T.: N-acetylaspartate and N-acetylaspartylglutamate levels in Alzheimer's disease post-mortem brain tissue. Mol. Chem. Neuropathol. 31:97-118, 1997. Go to original source... Go to PubMed...
    42. Patočka J., Krejčová G., Borovičková L. et al.: Humanin: natural peptide with neuroprotective effect. Homeostasis 42:77-78, 2003.
    43. Patočka J.: Memantine and its therapeutic potential in degenerative CNS disorders (Article in Czech). Psychiatrie 6:35-40, 2002.
    44. Patočka J., Slaninová J.: Humanin - new peptide in the etiology of Alzheimer's disease (Article in Czech). Čes. Slov. Psychiat. 98:221-222, 2002.
    45. Patočka J., Slaninová J.: Neurotoxic peptides related to Alzheimer's disease. Psychiatrie 7(Suppl. 2):99-102, 2003.
    46. Patočka J.: Some less known neuromediators. (Article in Czech). Psychiatrie 6(Suppl. 3):36-40, 2002.
    47. Permanne B., Adessi C., Fraga S. et al.: Are beta-sheet breaker peptides dissolving the therapeutic problem of Alzheimer's disease? J. Neural. Transm. 62 (Suppl.):293-301, 2002. Go to original source... Go to PubMed...
    48. Pompei P., Severini R., Pediconi D. et al.: Regulation of preprotachykinin-A gene expression in an animal model of Alzheimer's disease. J. Histochem. Cytochem. 49: 1469-1470, 2001. Go to original source... Go to PubMed...
    49. Reilly C.E.: Beta-sheet breaker peptides reverse conformation of pathogenic prion proteins. J. Neurol. 247:319-320, 2000.
    50. Sheppard P.W., Everall I., Anderton B.H.: Rapid tyrosine phosphorylation of neuronal proteins including tau and focal adhesion kinase in response to amyloidbeta peptide exposure: involvement of Src family protein kinases. J. Neurosci. 22:10-20, 2002. Go to original source... Go to PubMed...
    51. Sigalov E., Fridkin M., Brenneman D.E., Gozes I.: VIP-related protection against iodoacetate toxicity in pheochromocytoma (PC12) cells. A model for ischemic/hypoxic injury. J. Mol. Neurosci. 15:147-154, 2000. Go to original source... Go to PubMed...
    52. Sisodia S.S., Tanzi R.E: Special Issue: Alzheimer's disease. J. Mol. Neurosci. 17:99-270, 2001. Go to original source...
    53. Sisodia S.S., Annaert W., Kim S.H., De Strooper B.: Gammasecretase: never more enigmatic. Trends Neurosci. 24 (Suppl):S2-S6, 2001. Go to original source...
    54. Slaninová J., Patočka J.: Neuroprotective peptides related to Alzheimer's disease (In Czech). Psychiatrie 7(Suppl. 2): 122-123, 2003.
    55. Sokolowska P., Dejda A., Nowak J.Z: Neuroprotective role of PACAP, VIP, and PHI in the central nervous system (In Polish). Postepy Hig. Med. Dosw. 58:416-427, 2004.
    56. Steingart R.A., Solomon B., Brenneman D.E., Fridkin M., Gozes I.: VIP and peptides related to activity-dependent neurotrophic factor protect PC12 cells against oxidative stress. J. Mol. Neurosci. 15:137-145, 2000. Go to original source... Go to PubMed...
    57. Strunecká A., Patočka J.: Aluminofluoride complexes in the etiology of Alzheimer's disease. Struct. Bonding 104:139-180, 2003. Go to original source...
    58. Strunecká A., Patočka J.: Lithium and Alzheimer's disease (In Czech). Psychiatrie 8:13-16, 2004.
    59. Strunecká A., Patočka J., Connet P.: Fluorine in medicine. J. Appl. Biomed. 2:141-150, 2004. Go to original source...
    60. Thomas A.G., Olkowski J.L., Slusher B.S.: Neuroprotection afforded by NAAG and NAALADase inhibition requires glial cells and metabotropic glutamate receptor activation. Eur. J. Pharmacol. 426:35-38, 2001. Go to original source... Go to PubMed...
    61. Weinreb O., Bar-Am O., Amit T., Chillag-Talmor O., Youdim M.B.: Neuroprotection via pro-survival protein kinase C isoforms associated with Bcl-2 family members. FASEB J. 18:1471-1473, 2004. Go to original source... Go to PubMed...
    62. White D.M., Walker S., Brenneman D.E., Gozes I.: CREB contributes to the increased neurite outgrowth of sensory neurons induced by vasoactive intestinal polypeptide and activity-dependent neurotrophic factor. Brain Res. 868:31-38, 2000. Go to original source... Go to PubMed...
    63. Williamson R., Scales T., Clark B.R. et al.: Humanin, a newly identified neuroprotective factor, uses the G protein-coupled formylpeptide receptor-like-1 as a functional receptor. J. Immunol. 172:7078-7085, 2004. Go to original source... Go to PubMed...
    64. Xie J., Guo Q.: AATF protects neural cells against oxidative damage induced by amyloid beta-peptide. Neurobiol. Dis. 16:150-157, 2004. Go to original source... Go to PubMed...
    65. Zamostiano R., Pinhasov A., Gelber E. et al.: Cloning and characterization of the human activity-dependent neuroprotective protein. J. Biol. Chem. 276:708-714, 2001. Go to original source... Go to PubMed...
    66. Zamostiano R., Pinhasov A., Bassan M. et al.: A femtomolar-acting neuroprotective peptide induces intracellular increases in heat shock protein 60: a potential neuroprotective mechanism. Neurosci. Lett. 264:9-12, 1999. Go to original source... Go to PubMed...
    67. Zhu X., Wang Y., Ogawa O. et al.: Neuroprotective properties of Bcl-w in Alzheimer disease. J. Neurochem. 89:1233-1240, 2004. Go to original source... Go to PubMed...

    Return to the content